` HPHA (Heidelberg Pharma AG) vs DAX Index Comparison - Alpha Spread

HPHA
vs
D
DAX Index

Over the past 12 months, HPHA has underperformed DAX Index, delivering a return of +21% compared to the DAX Index's +23% growth.

Stocks Performance
HPHA vs DAX Index

Loading
HPHA
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
HPHA vs DAX Index

Loading
HPHA
DAX Index
Difference
www.alphaspread.com

Performance By Year
HPHA vs DAX Index

Loading
HPHA
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Heidelberg Pharma AG vs Peers

DAX Index
HPHA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Heidelberg Pharma AG
Glance View

Market Cap
138m EUR
Industry
Biotechnology

Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.

HPHA Intrinsic Value
2.42 EUR
Overvaluation 18%
Intrinsic Value
Price
Back to Top